Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026

Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026

Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products...

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026

Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral...

Company Drug

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Fineline Cube Apr 10, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National...

Company Drug

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Fineline Cube Apr 10, 2026

Duality Biologics Co., Ltd. (HKG: 9606), a U.S.-China biotech specializing in antibody-drug conjugates (ADCs), announced...

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that its novel drug candidate HSK42360 has been...

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026

Luye Pharma Group (HKG: 2186) announced first patient enrollment in a Phase II clinical study evaluating...

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Fineline Cube Apr 9, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that the US Food and Drug Administration (FDA) has granted...

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Fineline Cube Apr 9, 2026

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Sino Biopharm’s Chia Tai Tianqing Secures GDMPA Approval for Naldemedine in Greater Bay Area – World’s First Oral OIC Therapy Enters China

Fineline Cube Apr 9, 2026

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Limited...

Company Drug

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Fineline Cube Apr 9, 2026

UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Fineline Cube Apr 9, 2026

Shionogi Co., Ltd. (TYO: 4507) announced that its U.S. subsidiary, Shionogi Inc., has been awarded...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China’s National Medical Products Administration...

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Fineline Cube Apr 8, 2026

Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig,...

Company Drug

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

Fineline Cube Apr 8, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast...

Company Drug

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Fineline Cube Apr 8, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Fineline Cube Apr 7, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National...

Company Drug

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Fineline Cube Apr 7, 2026

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National...

Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer

Duality Biologics’ HER2-Targeted ADC DB-1303 (BNT323) Enters NMPA Review for Metastatic Breast Cancer

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Sino Biopharm’s Chia Tai Tianqing Secures GDMPA Approval for Naldemedine in Greater Bay Area – World’s First Oral OIC Therapy Enters China

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

You Missed

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Ribo Life Science Advances World’s Leading FXI-Targeting siRNA Vortosiran into Phase IIb for AF Stroke Prevention